Literature DB >> 18285463

Phosphoinositide 3-kinases p110alpha and p110beta regulate cell cycle entry, exhibiting distinct activation kinetics in G1 phase.

Miriam Marqués1, Amit Kumar, Isabel Cortés, Ana Gonzalez-García, Carmen Hernández, M Carmen Moreno-Ortiz, Ana C Carrera.   

Abstract

Phosphoinositide 3-kinase (PI3K) is an early signaling molecule that regulates cell growth and cell cycle entry. PI3K is activated immediately after growth factor receptor stimulation (at the G(0)/G(1) transition) and again in late G(1). The two ubiquitous PI3K isoforms (p110alpha and p110beta) are essential during embryonic development and are thought to control cell division. Nonetheless, it is presently unknown at which point each is activated during the cell cycle and whether or not they both control S-phase entry. We found that p110alpha was activated first in G(0)/G(1), followed by a minor p110beta activity peak. In late G(1), p110alpha activation preceded that of p110beta, which showed the maximum activity at this time. p110beta activation required Ras activity, whereas p110alpha was first activated by tyrosine kinases and then further induced by active Ras. Interference with p110alpha and -beta activity diminished the activation of downstream effectors with different kinetics, with a selective action of p110alpha in blocking early G(1) events. We show that inhibition of either p110alpha or p110beta reduced cell cycle entry. These results reveal that PI3Kalpha and -beta present distinct activation requirements and kinetics in G(1) phase, with a selective action of PI3Kalpha at the G(0)/G(1) phase transition. Nevertheless, PI3Kalpha and -beta both regulate S-phase entry.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18285463      PMCID: PMC2293125          DOI: 10.1128/MCB.01786-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  42 in total

1.  Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase.

Authors:  Lei Bi; Ichiro Okabe; David J Bernard; Robert L Nussbaum
Journal:  Mamm Genome       Date:  2002-03       Impact factor: 2.957

2.  A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.

Authors:  Guangchao Sui; Christina Soohoo; El Bachir Affar; Frédérique Gay; Yujiang Shi; William C Forrester; Yang Shi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

3.  Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit.

Authors:  Tung O Chan; Ulrich Rodeck; Andrew M Chan; Alec C Kimmelman; Susan E Rittenhouse; George Panayotou; Philip N Tsichlis
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

4.  Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry.

Authors:  Amit Kumar; Miriam Marqués; Ana C Carrera
Journal:  Mol Cell Biol       Date:  2006-10-02       Impact factor: 4.272

5.  Cell cycle-dependent dynamic association of cyclin/Cdk complexes with human DNA replication proteins.

Authors:  Isabelle Frouin; Alessandra Montecucco; Giuseppe Biamonti; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  EMBO J       Date:  2002-05-15       Impact factor: 11.598

Review 6.  Regulation of cell size in growth, development and human disease: PI3K, PKB and S6K.

Authors:  Sara C Kozma; George Thomas
Journal:  Bioessays       Date:  2002-01       Impact factor: 4.345

7.  Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice.

Authors:  Klaus Okkenhaug; Antonio Bilancio; Géraldine Farjot; Helen Priddle; Sara Sancho; Emma Peskett; Wayne Pearce; Stephen E Meek; Ashreena Salpekar; Michael D Waterfield; Andrew J H Smith; Bart Vanhaesebroeck
Journal:  Science       Date:  2002-07-18       Impact factor: 47.728

8.  Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E.

Authors:  Diane C Fingar; Sofie Salama; Christina Tsou; Ed Harlow; John Blenis
Journal:  Genes Dev       Date:  2002-06-15       Impact factor: 11.361

9.  A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle.

Authors:  Emma Shtivelman; Joshua Sussman; David Stokoe
Journal:  Curr Biol       Date:  2002-06-04       Impact factor: 10.834

10.  Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit.

Authors:  Nabil Miled; Ying Yan; Wai-Ching Hon; Olga Perisic; Marketa Zvelebil; Yuval Inbar; Dina Schneidman-Duhovny; Haim J Wolfson; Jonathan M Backer; Roger L Williams
Journal:  Science       Date:  2007-07-13       Impact factor: 47.728

View more
  33 in total

Review 1.  The emerging mechanisms of isoform-specific PI3K signalling.

Authors:  Bart Vanhaesebroeck; Julie Guillermet-Guibert; Mariona Graupera; Benoit Bilanges
Journal:  Nat Rev Mol Cell Biol       Date:  2010-04-09       Impact factor: 94.444

2.  Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair.

Authors:  Amit Kumar; Oscar Fernandez-Capetillo; Oscar Fernadez-Capetillo; Ana C Carrera
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

3.  Activity of any class IA PI3K isoform can sustain cell proliferation and survival.

Authors:  Lazaros C Foukas; Inma M Berenjeno; Alexander Gray; Asim Khwaja; Bart Vanhaesebroeck
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

4.  Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.

Authors:  Chenchen He; Shaofeng Duan; Liang Dong; Yifen Wang; Qingting Hu; Chunjing Liu; Marcus L Forrest; Jeffrey M Holzbeierlein; Suxia Han; Benyi Li
Journal:  Prostate       Date:  2017-06-20       Impact factor: 4.104

5.  SADB phosphorylation of gamma-tubulin regulates centrosome duplication.

Authors:  María Alvarado-Kristensson; María Josefa Rodríguez; Virginia Silió; José M Valpuesta; Ana C Carrera
Journal:  Nat Cell Biol       Date:  2009-08-02       Impact factor: 28.824

6.  Cell activation-induced phosphoinositide 3-kinase alpha/beta dimerization regulates PTEN activity.

Authors:  Vicente Pérez-García; Javier Redondo-Muñoz; Amit Kumar; Ana C Carrera
Journal:  Mol Cell Biol       Date:  2014-06-23       Impact factor: 4.272

7.  Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms.

Authors:  Christopher Stamatkin; Kelley L Ratermann; Colleen W Overley; Esther P Black
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

8.  Nuclear but not cytosolic phosphoinositide 3-kinase beta has an essential function in cell survival.

Authors:  Amit Kumar; Javier Redondo-Muñoz; Vicente Perez-García; Isabel Cortes; Monica Chagoyen; Ana C Carrera
Journal:  Mol Cell Biol       Date:  2011-03-07       Impact factor: 4.272

9.  Role of phosphoinositide 3-OH kinase p110β in skeletal myogenesis.

Authors:  Ronald W Matheny; Melissa A Riddle-Kottke; Luis A Leandry; Christine M Lynch; Mary N Abdalla; Alyssa V Geddis; David R Piper; Jean J Zhao
Journal:  Mol Cell Biol       Date:  2015-01-20       Impact factor: 4.272

10.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.